Jbm (Healthcare) Ltd
HKEX:2161
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.52
3.35
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Jbm (Healthcare) Ltd
Cost of Revenue
Jbm (Healthcare) Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Jbm (Healthcare) Ltd
HKEX:2161
|
Cost of Revenue
-HK$368.6m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Cost of Revenue
-HK$5B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-10%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Cost of Revenue
-ÂĄ7.4B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-6%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Cost of Revenue
-ÂĄ5.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-8%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Cost of Revenue
-HK$219.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Cost of Revenue
-$336.3m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-14%
|
|
Jbm (Healthcare) Ltd
Glance View
JBM (Healthcare) Ltd. functions as an investment holding company. The company employs 274 full-time employees The company went IPO on 2021-02-05. The firm operates its business through three segments. The Proprietary Chinese Medicines segment mainly distributes over the counter (OTC) proprietary Chinese medicines and concentrated Chinese medicine granule (CCMG) products. The Consumer Healthcare Products segment primarily distributes proprietary medicines in the form of OTC. The Health and Wellness Products segment sales and distributes health and wellness products. The firm operates business in domestic and overseas markets such as Southeast Asia, Europe, and North America.
See Also
What is Jbm (Healthcare) Ltd's Cost of Revenue?
Cost of Revenue
-368.6m
HKD
Based on the financial report for Mar 31, 2025, Jbm (Healthcare) Ltd's Cost of Revenue amounts to -368.6m HKD.
What is Jbm (Healthcare) Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-14%
Over the last year, the Cost of Revenue growth was -19%. The average annual Cost of Revenue growth rates for Jbm (Healthcare) Ltd have been -15% over the past three years , -14% over the past five years .